On Friday, October 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead's nucleotide analogue reverse transcriptase inhibitor, tenofovir disoproxil fumarate (brand name, Viread). The labeling requested was for the "treatment of HIV-1 infection in combination with…
Reports of Progress Toward Understanding How Some People Appear to Fight Off HIV Identifying "Resistance" Epitopes By Richard Jeffreys In the United States, long-term studies of HIV-infected and high-risk people have mainly involved gay men -- the group most heavily…
Nongovernmental Organization Access Effort Dealt Stealth Blow By Ivy League Development Institute "We observe no apparent correlation between access to antiretroviral treatment, which is uniformly poor across Africa, and patent status, which varies extensively by country and drug." -- Amir Attaran,…
Investigational New Drugs Currently Being Tested In Humans, By Class Nucleoside RTI 3 Non-nucleoside RTI 7 Protease inhibitor 4 Fusion/binding inhibitor 5 Cellular factors inhibitor 4 Other 2 Total 25 Source: Project Inform
Argentina International AIDS Society Conference Snoozer Prompts Systematic Review of Drug Pipeline By Mark Harrington "Underwhelmingly Innovative" The International AIDS Society inaugurated its new program of summer research meetings with a sleeper of a gathering in the southern hemisphere port…
Shudda, Cudda, Wudda: Reevaluating the Treatment Revolution After the Fall By David Barr "Six Years of Lost Data" David Barr revisits the changes to the federal when-to-start recommendations announced earlier this year and urges us to consider both the roots…
The Drug Development Pipeline, 2001 Development Terminated GW420867X/HBY1293 GlaxoSmithKline JAIDS 2000; also summer IAS meeting ALX40-4C Allelix Pharmaceuticals Formulation difficulties, lack of efficacy AMD3100 AnorMed Inc. Cardiac arrhythmias at high doses, lack of efficacy at low PD-178390 Parke-Davis Casualty of…
Model Physician/Patient Pair Are Latest to Feel the Fury of Fragile, Unforgiving Treatment Plan By David Barr "Data now exist which suggest that even HIV-specific immune function may be augmented with prolonged therapy, providing optimism that meaningful immune control might…
Antiretroviral Renegade Fights Fashion with Didanosine Duo, Betting His Future on Genetic Barriers By Mike Barr "Souped-Up Monotherapy" When it comes to the management of a fatal infection like HIV, it has been argued that self-experimentation seldom leads to knowledge…
The link between HLA types and HIV disease progression has been known for over a decade now from, among others, analyses of data from the Multi-Center AIDS Cohort (MACS). McMichael and colleagues have also documented CTL escape through the mutation…